Crăciun Rareș, Bumbu Andreea Livia, Ichim Vlad Andrei, Tanțău Alina Ioana, Tefas Cristian
Department of Internal Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8 Victor Babes Street, 400012 Cluj-Napoca, Romania.
Department of Gastroenterology, "Prof. Dr. Octavian Fodor" Institute of Gastroenterology and Hepatology, 19-21 Croitorilor Street, 400162 Cluj-Napoca, Romania.
J Clin Med. 2025 Jun 16;14(12):4291. doi: 10.3390/jcm14124291.
Artificial intelligence (AI) is rapidly transforming imaging modalities in inflammatory bowel disease (IBD), particularly in endoscopy and ultrasound. Despite their critical roles, both modalities are challenged by interobserver variability, subjectivity, and accessibility issues. AI offers significant potential to address these limitations by enhancing lesion detection, standardizing disease activity scoring, and supporting clinical decision-making. In endoscopy, deep convolutional neural networks have achieved high accuracy in detecting mucosal abnormalities and grading disease severity, reducing observer dependency and improving diagnostic consistency. AI-assisted colonoscopy systems have also demonstrated improvements in procedural quality metrics, including adenoma detection rates and withdrawal times. Similarly, AI applications in intestinal ultrasound show promise in automating measurements of bowel wall thickness, assessing vascularity, and distinguishing between inflammatory and fibrotic strictures, which are critical for tailored therapy decisions. Video capsule endoscopy has likewise benefited from AI, reducing interpretation times and enhancing the detection of subtle lesions. Despite these advancements, implementation challenges, including dataset quality, standardization, AI interpretability, clinician acceptance, and regulatory and ethical considerations, must be carefully addressed. The current review focuses on the most recent developments in the integration of AI into experimental designs, medical devices, and clinical workflows for optimizing diagnostic accuracy, treatment strategies, and patient outcomes in IBD management.
人工智能(AI)正在迅速改变炎症性肠病(IBD)的成像方式,尤其是在内镜检查和超声检查方面。尽管这两种检查方式起着关键作用,但它们都面临着观察者间差异、主观性和可及性问题的挑战。人工智能通过增强病变检测、标准化疾病活动评分以及支持临床决策,为解决这些局限性提供了巨大潜力。在内镜检查中,深度卷积神经网络在检测黏膜异常和对疾病严重程度进行分级方面已取得了很高的准确率,减少了对观察者的依赖并提高了诊断一致性。人工智能辅助结肠镜检查系统在包括腺瘤检出率和退镜时间等操作质量指标方面也有改善。同样,人工智能在肠道超声中的应用在自动化肠壁厚度测量、评估血管分布以及区分炎症性和纤维化狭窄方面显示出前景,这对于制定个性化治疗决策至关重要。视频胶囊内镜检查同样受益于人工智能,减少了解读时间并增强了对细微病变的检测。尽管取得了这些进展,但实施方面的挑战,包括数据集质量、标准化、人工智能的可解释性、临床医生的接受度以及监管和伦理考量,都必须得到认真解决。本综述重点关注将人工智能整合到实验设计、医疗设备和临床工作流程中的最新进展,以优化IBD管理中的诊断准确性、治疗策略和患者预后。